Christian R Frey
Overview
Explore the profile of Christian R Frey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
553
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fumagalli V, Di Lucia P, Venzin V, Bono E, Jordan R, Frey C, et al.
J Exp Med
. 2020 Aug;
217(11).
PMID: 32761167
Antibody-mediated clearance of hepatitis B surface antigen (HBsAg) from the circulation of chronically infected patients (i.e., seroconversion) is usually associated with increased HBV-specific T cell responsiveness. However, a causative link...
2.
Palazzo A, Herter S, Grosmaire L, Jones R, Frey C, Limani F, et al.
J Immunol
. 2018 Feb;
200(7):2304-2312.
PMID: 29453281
Idelalisib is a highly selective oral inhibitor of PI3Kδ indicated for the treatment of patients with relapsed chronic lymphocytic leukemia in combination with rituximab. Despite additive clinical effects, previous studies...
3.
Steadman V, Pettit S, Poullennec K, Lazarides L, Keats A, Dean D, et al.
J Med Chem
. 2017 Jan;
60(3):1000-1017.
PMID: 28075591
Cyclophilin inhibition has been a target for the treatment of hepatitis C and other diseases, but the generation of potent, drug-like molecules through chemical synthesis has been challenging. In this...
4.
Bam R, Hansen D, Irrinki A, Mulato A, Jones G, Hesselgesser J, et al.
Antimicrob Agents Chemother
. 2016 Nov;
61(1).
PMID: 27799218
GS-9620 is a potent and selective oral Toll-like receptor 7 (TLR7) agonist that directly activates plasmacytoid dendritic cells (pDCs). GS-9620 suppressed hepatitis B virus (HBV) in animal models of chronic...
5.
Birkus G, Bam R, Willkom M, Frey C, Tsai L, Stray K, et al.
Antimicrob Agents Chemother
. 2015 Oct;
60(1):316-22.
PMID: 26503655
Tenofovir alafenamide fumarate (TAF) is an oral phosphonoamidate prodrug of the HIV reverse transcriptase nucleotide inhibitor tenofovir (TFV). Previous studies suggested a principal role for the lysosomal serine protease cathepsin...
6.
Fosdick A, Zheng J, Pflanz S, Frey C, Hesselgesser J, Halcomb R, et al.
J Pharmacol Exp Ther
. 2013 Oct;
348(1):96-105.
PMID: 24133297
GS-9620 [8-(3-(pyrrolidin-1-ylmethyl)benzyl)-4-amino-2-butoxy-7,8-dihydropteridin-6(5H)-one] is a potent, orally bioavailable small-molecule agonist of Toll-like receptor 7 (TLR7) developed for finite treatment of chronic hepatitis B viral (HBV) infection, with the goal of inducing...
7.
Frey C, Andrei G, Votruba I, Cannizzaro C, Han B, Fung W, et al.
Anticancer Res
. 2013 May;
33(5):1899-912.
PMID: 23645737
Background/aim: GS 9219 is a double prodrug of antiproliferative nucleotide analog 9-(2-Phosphonylmethoxyethyl)guanine (PMEG), with potent in vivo efficacy against various hematological malignancies. This study investigates the role of adenosine deaminase-like...
8.
Lopatin U, Wolfgang G, Tumas D, Frey C, Ohmstede C, Hesselgesser J, et al.
Antivir Ther
. 2013 Feb;
18(3):409-18.
PMID: 23416308
Background: GS-9620 is a novel oral agonist of Toll-like receptor 7 (TLR7) in development for the treatment of chronic viral hepatitis. TLR7 is a highly conserved innate immune receptor expressed...
9.
Lanford R, Guerra B, Chavez D, Giavedoni L, Hodara V, Brasky K, et al.
Gastroenterology
. 2013 Feb;
144(7):1508-17, 1517.e1-10.
PMID: 23415804
Background & Aims: Direct-acting antiviral agents suppress hepatitis B virus (HBV) load, but they require life-long use. Stimulation of the innate immune system could increase its ability to control the...
10.
Birkus G, Kutty N, Frey C, Shribata R, Chou T, Wagner C, et al.
Antimicrob Agents Chemother
. 2011 Mar;
55(5):2166-73.
PMID: 21383096
GS-9191, a bis-amidate prodrug of the nucleotide analog 9-(2-phosphonylmethoxyethyl)-N6-cyclopropyl-2,6-diaminopurine (cPrPMEDAP), was designed as a topical agent for the treatment of papillomavirus-associated proliferative disorders, such as genital warts. In this study,...